$20 Million

Transition Theraeputics

Follow-on Offering

Sole Bookrunner, February 2015

Confidentially Marketed Public Offering

Developer of therapeutics for disease indications. The company provides a product for the treatment of Alzheimer's disease and for the treatment of diabetes.